Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Concurrence of Talaromycosis and Kaposi Sarcoma in an HIV-Infected Patient: A Case Report

Author(s): Xingguo Miao, Hui Ye, Shoufeng Yang and Feifei Su*

Volume 19, Issue 2, 2021

Published on: 05 November, 2020

Page: [195 - 198] Pages: 4

DOI: 10.2174/1570162X18999201105161137

Price: $65

Abstract

Background: Concurrence of talaromycosis, an infection caused by the opportunistic fungal pathogen Talaromyces marneffei and Kaposi sarcoma, a common vascular tumor, is a rare but severe medical condition in patients infected with the human immunodeficiency virus (HIV). Despite poor outcomes, the clinical characteristics and management strategies for HIV-infected patients with comorbid Kaposi sarcoma and talaromycosis have not been well documented.

Case presentation: A 33-year-old HIV-positive male patient presented to the Department of Infectious Diseases at Wenzhou Central Hospital with cough, sputum expectoration, hemoptysis, rashes on the feet and violaceous plaques in the oral cavity. Chest computed tomography (CT) showed bilateral nodules, patchy shadows and lymphadenectasis. Skin biopsy and histopathological examination indicated Kaposi sarcoma. T. marneffei was isolated from blood cultures and suggested talaromycosis. The patient’s overall conditions significantly improved following initiation of combination antiretroviral therapy (cART) and chemotherapy for Kaposi sarcoma and antifungal treatment for talaromycosis.

Conclusion: Severe medical conditions such as Kaposi sarcoma and talaromycosis may coexist in HIV-infected patients and pose an increased risk of mortality. Etiological diagnosis and treatment are the keys to the successful management of HIV-infected patients with these concurrent conditions.

Keywords: HIV infection, talaromycosis, kaposi sarcoma, concurrence, management, cART.

« Previous
Graphical Abstract

[1]
Yaqub S, Stepenaskie SA, Farshami FJ, et al. Kaposi sarcoma as a cutaneous vasculitis mimic: Diagnosis and treatment. J Clin Aesthet Dermatol 2019; 12(11): 23-6.
[PMID: 32038753]
[2]
Li X, Hu W, Wan Q, et al. Non-HIV talaromycosis: Radiological and clinical analysis. Medicine (Baltimore) 2020; 99(10): e19185.
[http://dx.doi.org/10.1097/MD.0000000000019185] [PMID: 32150056]
[3]
Pongpech N, Rotjanapan P. Absence of cutaneous involvement in disseminated Talaromyces marneffei infection in an AIDS patient: a case report and literature review. Infect Drug Resist 2019; 12: 1493-9.
[http://dx.doi.org/10.2147/IDR.S207819] [PMID: 31239726]
[4]
Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia 2013; 175(1-2): 57-67.
[http://dx.doi.org/10.1007/s11046-012-9577-0] [PMID: 22983901]
[5]
Hoffmann C, Sabranski M, Esser S. HIV-Associated Kaposi’s Sarcoma. Oncol Res Treat 2017; 40(3): 94-8.
[http://dx.doi.org/10.1159/000455971] [PMID: 28259888]
[6]
AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi sarcoma risk in human immunodeficiency virus-positive adults across 5 continents: A multiregional multicohort study. Clin Infect Dis 2017; 65(8): 1316-26.
[http://dx.doi.org/10.1093/cid/cix480] [PMID: 28531260]
[7]
Xiao J, Gao G, Li Y, et al. Spectrums of opportunistic infections and malignancies in HIV-infected patients in tertiary care hospital, China. PLoS One 2013; 8(10): e75915.
[http://dx.doi.org/10.1371/journal.pone.0075915] [PMID: 24204583]
[8]
Chen J, Zhang R, Shen Y, et al. Clinical characteristics and prognosis of penicilliosis among human immunodeficiency virus-infected patients in Eastern China. Am J Trop Med Hyg 2017; 96(6): 1350-4.
[http://dx.doi.org/10.4269/ajtmh.16-0521] [PMID: 28719279]
[9]
Papa V, Giustiniani MC, Lopetuso LR, Papa A. Human herpesvirus 8-associated colonic Kaposi’s sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature. BMC Gastroenterol 2020; 20(1): 76.
[http://dx.doi.org/10.1186/s12876-020-01221-2] [PMID: 32204698]
[10]
Reid E, Suneja G, Ambinder RF, et al. CGC. AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17(2): 171-89.
[http://dx.doi.org/10.6004/jnccn.2019.0008] [PMID: 30787130]
[11]
Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis 2013; 13: 464.
[http://dx.doi.org/10.1186/1471-2334-13-464] [PMID: 24094273]
[12]
A D, S T. A 12-case series of Penicillium marneffei pneumonia Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2006; 89 (4 ): 441 -7 .
[13]
Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. National Institutes of Health; Centers for Disease Control and Prevention; HIV Medicine Association of the Infectious Diseases Society of America. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58(9): 1308-11.
[http://dx.doi.org/10.1093/cid/ciu094] [PMID: 24585567]
[14]
Thanh NT, Vinh LD, Liem NT, et al. Clinical features of three patients with paradoxical immune reconstitution inflammatory syndrome associated with Talaromyces marneffei infection. Med Mycol Case Rep 2016; 19: 33-7.
[http://dx.doi.org/10.1016/j.mmcr.2016.12.005] [PMID: 29379703]

Rights & Permissions Print Cite
Article Metrics
37
2
© 2024 Bentham Science Publishers | Privacy Policy